B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
University of Alabama at Birmingham
Summary
This study will examine how various FDA-approved seasonal influenza vaccine types, used in a manner consistent with their approved use, impact the characteristics of influenza specific antibodies in humans, and how these responses differ based on age and prior immunization history.
Description
This study is particularly focused on studying antibodies, a protein in blood that react with foreign substances (such as bacteria and viruses) to help eliminate them. This study will examine antibodies and the cells that they are produced by, B cells that develop in response to the influenza vaccine. The majority of antibodies that develop following seasonal influenza vaccine are highly specific for particular influenza strain that comprises the influenza vaccine, necessitating the annual reformulation of the influenza vaccine to match strains expected to be in circulation for the upcoming s…
Eligibility
- Age range
- 18–80 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Participation in ancillary clinical research study * Able to give informed consent * Age 18-50 years old for Arm 1 and Arm 2 * Age 65-80 years old for Arm 3, Arm 4, and Arm 5 * Weight of at least 110 lbs as determined by self-reporting Exclusion Criteria: * Inability to give informed consent * Refusal or inability to have blood drawn or participate in study procedures * Previous adverse reaction to influenza vaccine or medical history contraindicated for receiving influenza vaccine, including but not limited to: 1. History of Guillain-Barre Syndrome 2. History of…
Interventions
- DrugFluzone
inactivated seasonal influenza vaccine
- DrugFlucelvax
inactivated seasonal influenza vaccine
- DrugFluzone High-Dose
inactivated seasonal influenza vaccine
- DrugFluad
inactivated seasonal influenza vaccine
Location
- University of Alabama at BirminghamBirmingham, Alabama